Participants with Diffuse Large B-Cell Lymphoma (DLBCL) and large B cell lymphoma for B-Cell Lymphoma
This trial will evaluate a new therapy for relapsed/refractory B-cell lymphoma to see if it is safe and effective, and to determine the best dose to use.
- B-Cell Lymphoma
- Non-Hodgkin's Lymphoma
- Diffuse Large B-Cell Lymphoma, Non-Germinal Center B-Cell Subtype
- Mediastinal Large B Cell Lymphoma
1 Primary · 0 Secondary · Reporting Duration: up to 1 year
1 Treatment Group
Participants with Diffuse Large B-Cell Lymphoma (DLBCL) and large B cell lymphom...
1 of 1
30 Total Participants · 1 Treatment Group
Primary Treatment: Participants with Diffuse Large B-Cell Lymphoma (DLBCL) and large B cell lymphoma · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What risks do people with Diffuse Large B-Cell Lymphoma (DLBCL) and large B cell lymphoma face?
"Since this is a Phase 1 trial, with limited data supporting the safety and efficacy of Participants with Diffuse Large B-Cell Lymphoma (DLBCL) and large B cell lymphoma, we gave it a score of 1." - Anonymous Online Contributor
What is the cap on the number of participants in this trial?
"Affirmative, the clinicaltrials.gov data indicates that this study is actively seeking enrollees and was originally posted on February 23rd 2023 with a last edit date of February 24th 2023. The trial requires 30 participants to be recruited from one medical facility." - Anonymous Online Contributor
Are there any vacant positions for patients within this trial?
"Affirmative. According to clinicaltrials.gov, the trial is actively recruiting participants with its initial posting on February 23rd 2023 and last update made 24 hours later. The single research site requires 30 enrollees for completion of this experiment." - Anonymous Online Contributor